Lexicon Pharmaceuticals was founded in 1995 and is headquartered in Spring, US

Chairman of the Board

Executive Vice President of Clinical Development and Chief Medical Officer

Executive Vice President and Chief Financial Officer

Vice President of Finance and Accounting

Executive Vice President, Commercial Supply Operations

President and Chief Executive Officer and Director

Lexicon Pharmaceuticals has offices in Spring, The Woodlands, Boston, Philadelphia and in 27 other locations

Spring, US (HQ)

8800 Technology Forest Place

Lexicon Pharmaceuticals's revenue was reported to be $18.3 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 18.3 m |

## Gross profit (Q1, 2017) | 18.1 m |

## Gross profit margin (Q1, 2017), % | 99% |

## Net income (Q1, 2017) | (34.9 m) |

## EBIT (Q1, 2017) | (42.5 m) |

## Market capitalization (25-Jul-2017) | 1.8 b |

## Cash (31-Mar-2017) | 2.5 m |

Lexicon Pharmaceuticals's current market capitalization is $1.8 b.

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 2.2 m | 22.9 m | 130 m | 83.3 m |

## Revenue growth, % | 929% | 469% | (36%) | |

## Operating expense total | 104.6 m | 123.2 m | 128.5 m | 220.5 m |

## EBIT | (102.4 m) | (100.4 m) | 1.5 m | (137.2 m) |

## EBIT margin, % | (4607%) | (439%) | 1% | (165%) |

## Interest expense | 2 m | 2.3 m | 6.7 m | 6.6 m |

## Interest income | 157 k | 2.3 m | 572 k | 2.3 m |

## Pre tax profit | (104.1 m) | (100.4 m) | (4.7 m) | (141.4 m) |

## Net Income | (104.1 m) | (100.3 m) | (4.7 m) | (141.4 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 676 k | 419 k | 1.8 m | 376 k | 566 k | 20.1 m | 27.7 m | 18.3 m | |

## Cost of goods sold | 225 k | ||||||||

## Gross profit | 18.1 m | ||||||||

## Gross profit Margin, % | 99% | ||||||||

## EBIT | (26.1 m) | (40.3 m) | (26.5 m) | (26.7 m) | (33.7 m) | (33.9 m) | (37 m) | (34.9 m) | (42.5 m) |

## EBIT margin, % | (3863%) | (9627%) | (1480%) | (7098%) | (5950%) | (184%) | (126%) | (232%) | |

## Interest income | 4 k | 5 k | 153 k | 269 k | 82 k | 637 k | 547 k | 564 k | 530 k |

## Net Income | (34.9 m) | (73 m) | (109 m) | (34.9 m) |

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} |
---|---|---|---|

## Cash | 37.5 m | 137.3 m | 46.6 m |

## Current Assets | 134.6 m | 369 m | 357.9 m |

## Goodwill | 44.5 m | 44.5 m | 44.5 m |

## Total Assets | 274.2 m | 471.4 m | 475.6 m |

## Accounts Payable | 9.7 m | 13.1 m | 52.9 m |

## Total Debt | 21.9 m | 107.7 m | 101.4 m |

## Current Liabilities | 19.3 m | 45 m | 164.6 m |

## Total Liabilities | 318.2 m | ||

## Additional Paid-in Capital | 1.2 b | 1.4 b | 1.4 b |

## Retained Earnings | (1 b) | (1.1 b) | (1.3 b) |

## Total Equity | 170.2 m | 284 m | 157.4 m |

## Debt to Equity Ratio | 0.1 x | 0.4 x | 0.6 x |

## Debt to Assets Ratio | 0.1 x | 0.2 x | 0.2 x |

## Financial Leverage | 1.6 x | 1.7 x | 3 x |

USD | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|

## Cash | 9.7 m | 61.7 m | 24.7 m | 38.4 m | 38.8 m | 2.5 m |

## Inventories | 236 k | |||||

## Current Assets | 313.8 m | 288.9 m | 492.2 m | 439.5 m | 398.7 m | 279.1 m |

## Goodwill | 44.5 m | 44.5 m | 44.5 m | 44.5 m | 44.5 m | 44.5 m |

## Total Assets | 416 m | 391.1 m | 611.3 m | 558.1 m | 516.9 m | 396.3 m |

## Accounts Payable | 11.3 m | 16.4 m | 25.5 m | 28.2 m | 41.5 m | 41.9 m |

## Current Liabilities | 43.6 m | 51.8 m | 121.9 m | 131 m | 170.1 m | 137.1 m |

## Additional Paid-in Capital | 1.4 b | 1.4 b | 1.4 b | 1.4 b | 1.4 b | 1.4 b |

## Retained Earnings | (1.2 b) | (1.2 b) | (1.1 b) | (1.2 b) | (1.2 b) | (1.3 b) |

## Total Equity | 231.5 m | 197.9 m | 252.9 m | 217.3 m | 185.2 m | 134.6 m |

## Financial Leverage | 1.8 x | 2 x | 2.4 x | 2.6 x | 2.8 x | 2.9 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} |
---|---|---|---|

## Depreciation and Amortization | 2.1 m | ||

## Accounts Receivable | (4.1 m) | ||

## Cash From Operating Activities | (91.1 m) | (75.6 m) | (175.6 m) |

## Purchases of PP&E | (1.7 m) | (80 k) | (231 k) |

## Cash From Investing Activities | 99.5 m | (108.4 m) | 18.3 m |

## Cash From Financing Activities | (1.4 m) | 283.8 m | 987 k |

## Interest Paid | 1.9 m | 1.8 m | 6.1 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (34.9 m) | (73 m) | (109 m) | (34.9 m) | |||||

## Depreciation and Amortization | 1.2 m | 1.7 m | 355 k | 601 k | 661 k | 521 k | 1 m | 1.5 m | 634 k |

## Accounts Receivable | 509 k | 625 k | 865 k | 719 k | 963 k | 170 k | (107 k) | 173 k | (1.2 m) |

## Cash From Operating Activities | (50 m) | (71.2 m) | (23.5 m) | (55.7 m) | (81.1 m) | (43.7 m) | (91.6 m) | (126.8 m) | (85.5 m) |

## Purchases of PP&E | (39 k) | (46 k) | (17 k) | (480 k) | (664 k) | (54 k) | (67 k) | (83 k) | (92 k) |

## Cash From Investing Activities | 41.8 m | 62.3 m | (71 m) | (70.7 m) | 7.1 m | (133.6 m) | (72.1 m) | (38.2 m) | 42.5 m |

## Cash From Financing Activities | (1.6 m) | (1.9 m) | (830 k) | (1.2 m) | (1.6 m) | (928 k) | (857 k) | 827 k | (1.1 m) |

## Interest Paid | 896 k | 1.4 m | 412 k | 3.2 m | 3.6 m | 378 k | 3 m | 3.4 m | 332 k |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 108.9 k |

## Financial Leverage | 2.9 x |